New hope for lupus patients: drug trial aims to tame overactive immune system
NCT ID NCT04582136
Summary
This study is testing if adding the drug sirolimus to standard lupus treatment can better control the disease in adults who still have active symptoms. About 146 participants will receive either sirolimus or a placebo pill for 24 weeks, followed by an extension period where everyone gets the drug. The main goal is to see if sirolimus helps reduce overall disease activity and flare-ups more effectively than current treatments alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100053, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Conditions
Explore the condition pages connected to this study.